Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 850
Last updated 2017-03-10
Summary
This study is the first phase of a trial examining decision making about vaccines. This phase tests the impact of targeted vaccine-focused health messages on vaccine beliefs held by parents of young children and pre-adolescents. The participant's vaccine beliefs will be assessed at baseline. Two weeks later, the participant's moral matrix will be assessed. A vaccine-related message that appeals to the individual's three most or least emphasized moral foundations will then be presented. Immediately afterwards, vaccine beliefs will be assessed to determine the impact of the message.
Conditions
- Childhood Vaccinations
Interventions
- BEHAVIORAL
-
Baseline Survey
The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
- BEHAVIORAL
-
Pre-intervention Survey
Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
- BEHAVIORAL
-
Morally Congruent Message
Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs. Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized.
- BEHAVIORAL
-
Morally Non-Congruent Message
Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized.
- BEHAVIORAL
-
Control Message
Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
- BEHAVIORAL
-
Post-Intervention Survey
Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
Sponsors & Collaborators
-
Emory University
lead OTHER
Principal Investigators
-
Saad B Omer, BBS, MPH, PhD · Emory University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-08-31
- Primary Completion
- 2016-10-31
- Completion
- 2016-10-31
Countries
- United States
Study Locations
More Related Trials
-
Text Message Reminder-Recalls For Early Childhood Vaccination
NCT01199666 ·Status: COMPLETED ·Phase: NA
-
Motivational Interviewing and Vaccine Hesitancy in Children
NCT03934008 ·Status: COMPLETED
-
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
NCT06603090 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years
NCT06314685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
NCT04689165 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age
NCT02919293 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
NCT05252715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Educational Videos to Address Vaccine Hesitancy in Childhood Immunization
NCT05390697 ·Status: COMPLETED ·Phase: NA
-
Impact of PACV Administration on Vaccine Hesitancy
NCT04450940 ·Status: COMPLETED ·Phase: NA
-
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
NCT00381615 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
NCT06314880 ·Status: RECRUITING ·Phase: PHASE1
-
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
NCT03205371 ·Status: COMPLETED ·Phase: PHASE3
-
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
NCT01823536 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
NCT00384397 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
NCT06337071 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT02878291 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months
NCT06314659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
NCT00616421 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
NCT02692599 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
NCT04540185 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
NCT03537508 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age
NCT00643916 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052 ·Status: COMPLETED ·Phase: PHASE1
-
SMS HPV Vaccine Reminders
NCT05151367 ·Status: COMPLETED ·Phase: NA